SymbolMAZE
NameMAZE THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address171 OYSTER POINT BOULEVARD,SUITE 300, SAN FRANCISCO, California, 94080, United States
Telephone6508505070
Fax
Email
Websitehttps://www.mazetx.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001842295
Description

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease. We initiated a Phase 2 trial of our lead drug candidate, MZE829, in November 2024.

Additional info from NASDAQ:
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease. We initiated a Phase 2 trial of our lead drug candidate, MZE829, in November 2024.

2026-07-02 20:29

Bernstein Harold 🟡 adjusted position in 14.6K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $30.34 Transaction Date: Jul 01, 2026 | Filing ID: 000025

Read more
2026-07-02 20:28

Coloma Jason V 🔴 sold 34.5K shares of Maze Therapeutics, Inc. (MAZE) at $30.44 ($1.0M) Transaction Date: Jul 01, 2026 | Filing ID: 000014

Read more
2026-07-01 20:04

📋 Coloma Jason V (Officer) plans to sell 35K shares of Maze Therapeutics, Inc. (at $29.98 each, total $1.0M) Filed: Jul 01, 2026 | ID: 000748

Read more
2026-06-24 20:14

Coloma Jason V 🔴 sold 27.9K shares of Maze Therapeutics, Inc. (MAZE) at $26.05 Transaction Date: Jun 22, 2026 | Filing ID: 000012

Read more
2026-06-10 20:31

SPIEGELMAN DANIEL K 🟢 acquired 18.0K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $23.58 Transaction Date: Jun 08, 2026 | Filing ID: 000004

Read more
2026-06-10 20:30

SCHELLER RICHARD H 🟢 acquired 18.0K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $23.58 Transaction Date: Jun 08, 2026 | Filing ID: 000002

Read more
2026-06-10 20:28

Lim Jonathan E 🟢 acquired 18.0K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $23.58 Transaction Date: Jun 08, 2026 | Filing ID: 000002

Read more
2026-06-10 20:26

Hoppenot Herve 🟢 acquired 18.0K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $23.58 Transaction Date: Jun 08, 2026 | Filing ID: 000007

Read more
2026-06-10 20:25

HOMCY CHARLES J 🟢 acquired 18.0K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $23.58 Transaction Date: Jun 08, 2026 | Filing ID: 000004

Read more
2026-06-10 20:23

Andrews Nancy C 🟢 acquired 18.0K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $23.58 Transaction Date: Jun 08, 2026 | Filing ID: 000002

Read more